Oukseub Lee

US Patent:

20140018435, Jan 16, 2014

Filed:

May 30, 2013

Appl. No.:

13/906009

Inventors:

Robert Chatterton - Chicago IL, US
Seema Khan - Chicago IL, US
Oukseub Lee - Morton Grove IL, US
Yang Yang - Chicago IL, US

International Classification:

A61K 47/48
A61K 31/138

US Classification:

514648

Abstract:

The invention provides for compositions for transdermal delivery of a therapeutic agent associated with a surface modified poly(amidoamine) PAMAM dendrimer, wherein the surface modified dendrimer increased skin penetration of the therapeutic agent. The invention particularly provides for compositions and methods for transdermal delivery of anticancer and chemo-preventive agents.

US Patent:

20190209498, Jul 11, 2019

Filed:

Mar 13, 2019

Appl. No.:

16/352167

Inventors:

- Evanston IL, US
Oukseub Lee - Morton Grove IL, US

Assignee:

Northwestern University - Evanston IL

International Classification:

A61K 31/138
A61K 9/06
A61K 9/00
A61K 47/12
A61K 47/10

Abstract:

Disclosed are methods and topical formulations for treating and/or preventing cell proliferative diseases and disorders including breast cancer and ductal carcinoma is situ (DCIS) using local transdermal therapy (LTT). The disclosed methods typically include administering topically to the breast or breasts of the patient a topical formulation comprising an effective dose of the tamoxifen metabolite, N-desmethyl-4-hydroxytamoxifen (i.e., endoxifen or ENX) for treating breast cancer. The topical formulation may be described as a transdermal formulation and the topical formulation may comprise, consist essentially of, or consist of endoxifen as an active ingredient.

US Patent:

20180104196, Apr 19, 2018

Filed:

Dec 14, 2017

Appl. No.:

15/842523

Inventors:

- Evanston IL, US
Oukseub Lee - Morton Grove IL, US

Assignee:

Northwestern University - Evanston IL

International Classification:

A61K 31/138
A61K 47/12
A61K 9/00
A61K 9/06
A61K 47/10

Abstract:

Disclosed are methods and topical formulations for treating and/or preventing cell proliferative diseases and disorders including breast cancer and ductal carcinoma is situ (DCIS) using local transdermal therapy (LTT). The disclosed methods typically include administering topically to the breast or breasts of the patient a topical formulation comprising an effective dose of the tamoxifen metabolite, N-desmethyl-4-hydroxytamoxifen (i.e., endoxifen or ENX) for treating breast cancer. The topical formulation may be described as a transdermal formulation and the topical formulation may comprise, consist essentially of, or consist of endoxifen as an active ingredient.

US Patent:

20170304232, Oct 26, 2017

Filed:

Apr 20, 2017

Appl. No.:

15/492641

Inventors:

- Evanston IL, US
Oukseub Lee - Morton Grove IL, US

Assignee:

Northwestern University - Evanston IL

International Classification:

A61K 31/138
A61K 47/10
A61K 9/06
A61K 47/12
A61K 9/00

Abstract:

Disclosed are methods and topical formulations for treating and/or preventing cell proliferative diseases and disorders including breast cancer and ductal carcinoma is situ (DCIS) using local transdermal therapy (LTT). The disclosed methods typically include administering topically to the breast or breasts of the patient a topical formulation comprising an effective dose of the tamoxifen metabolite, N-desmethyl-4-hydroxytamoxifen (i.e., endoxifen or ENX) for treating breast cancer. The topical formulation may be described as a transdermal formulation and the topical formulation may comprise, consist essentially of, or consist of endoxifen as an active ingredient.